KEY vs RXRX · P/E 13, rev $7.51B vs rev $58.8M
KeyCorp (KEY) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
KeyCorp (KEY) is a banks - regional company listed on US.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
KEY currently screens at market cap $22.64B and trailing P/E 12.8. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the KEY and RXRX stock pages for the full models.
Not investment advice.